Trial Profile
A phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study evaluating the efficacy and safety of CNTO 148 [golimumab] administered subcutaneously in symptomatic subjects with severe persistent asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jul 2020
Price :
$35
*
At a glance
- Drugs Golimumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Janssen Biotech
- 31 Jul 2012 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 01 Apr 2009 Results reported as published in the American Journal of Respiratory and Critical Care Medicine.
- 23 Nov 2008 309 patients were enrolled, according to clinicaltrials.gov.